A Quality Ensuring Project With Focus On Patients With Cardiovascular Diseases As Well As Type 2 Diabetes.

Diabetes Mellitus, Type 2 Clinical Trial

Official title:

Patient And Physician Alliance -Guideline Education Treatment Optimization

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00415428
• Other study ID #: A2581154
• Status: Completed
• Start date: January 2007
• Est. completion date: September 2008

Study information

• Verified date: February 2021
• Source: Pfizer
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The overall objective is to increase the adherence to national guidelines for patients with established CVD and/or Type 2 diabetes by means of repeated post-graduate educational meetings and regular evaluation of the optimisation initiatives, demonstrated by improvement of goal attainment in general practice.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2776
• Est. completion date: September 2008
• Est. primary completion date: September 2008
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subjects had to meet all of the inclusion criteria to be eligible for enrollment into the study. The following subjects qualify for inclusion in the study:

• Subjects for whom measurement of total cholesterol, low density lipoprotein (LDL) cholesterol, blood pressure (BP) and glycosylated hemoglobin (HbA1c) was planned independently of this observational study and for whom baseline values were or became available.

• Subjects with known CVD diagnosed > or = 6 months before inclusion

• Previous myocardial infarction

• Ischemic heart disease (stable and unstable angina pectoris)

• Ischemic apoplexy

• Peripheral arterial disease

• And/Or

• Subjects with T2D diagnosed > or = 6 months before inclusion

• At least 50% of the subjects had to have CVD as the primary diagnosis. It was allowed for a secondary diagnosis to be <6 months before inclusion.

Exclusion Criteria:

• Subjects presenting with any of the following were not to be included in the study:

• Life expectancy of < or = 2 years

• Unable/unwilling to understand/follow instructions

• Taking part in a clinical study involving an investigational drug

• Followed by a specialist for their CVD and/or T2D at the time of inclusion in the study

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 2
• Heart Diseases

Intervention

Behavioral:
• Patient adherence to national educational guidelines.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

External Links

•   To obtain contact information for a study center near you, click here.